S. IsmailD. J. BackG. EdwardsK. Na BangchangJ. KarbwangUniversity of LiverpoolLiverpool School of Tropical MedicineMahidol University2018-07-042018-07-041995-03-01European Journal of Clinical Pharmacology. Vol.48, No.1 (1995), 65-6914321041003169702-s2.0-0028920215https://repository.li.mahidol.ac.th/handle/20.500.14594/17440Investigations in animals have suggested that conjugation of paracetamol may be reduced in malaria. We have measured plasma concentrations and the urinary excretion of paracetamol and its phase II metabolites in eight Thai patients during uncomplicated falciparum malaria and in convalescence, following a 1000 mg single oral dose. The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml·min-1·kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l·kg-1) of paracetamol were similar during malaria and convalescence. In addition, the urinary excretion of paracetamol and its major phase II metabolites and their formation clearances from paracetamol were not significantly different between the two study phases. These data show that clinical malaria infection has no effect on the conjugation of paracetamol in man. © 1995 Springer-Verlag.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1007/BF00202175